FDA APPROVES G1 THERAPEUTICS’ COSELA™ (TRILACICLIB): THE FIRST AND ONLY MYELOPROTECTION THERAPY TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION

Press/Media

Period18 Feb 2021

Media coverage

1

Media coverage